The pioneering monoclonal antibody is for Essential Thrombocythemia (ET) and Polycythemia Vera (PV), rare chronic blood cancers with limited treatment options
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
Subscribe To Our Newsletter & Stay Updated
